SPECIALTY GUIDELINE MANAGEMENT

KISQALI (ribociclib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

- 1. Kisqali is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
- 2. Kisqali is indicated in combination with fulvestrant for the treatment of postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.

B. Compendial Uses

Kisqali is indicated in combination with tamoxifen for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status is necessary to initiate the prior authorization review.

III. CRITERIA FOR INITIAL APPROVAL

Breast cancer

Authorization of 12 months may be granted to members for the treatment of HR-positive, HER2-negative recurrent, advanced, or metastatic breast cancer when Kisqali is used in combination with an aromatase inhibitor, fulvestrant, or tamoxifen.

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continuation of therapy for an indication outlined in section III when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

V. REFERENCES

1. Kisqali [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2018.

Kisqali 1639-A SGM P2019b

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s)	
1639-A	

2. The NCCN Drugs & Biologics Compendium® © 2019 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed August 12, 2019.

Kisqali 1639-A SGM P2019b

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of